The S&P 500 Is Expensive, but These 3 Dividend Stocks Still Look Like Bargains
The S&P 500 was up about 11% entering Tuesday, helped by tech gains amid Iran-war and oil-price concerns and expectations of higher interest rates. The article highlights dividend stocks it says look undervalued: AbbVie (forward P/E 15, dividend yield 3.3%, free cash flow just under $20B), CVS Health (forward P/E 12, yield 2.9%, free cash flow $7.4B vs dividends $3.4B), and Verizon (forward P/E just under 10, yield 5.9%, free cash flow nearly $20B vs annual dividends $11.5B; adjusted earnings gr
Bullish valuation framing around forward earnings and dividend coverage; no new company-specific catalyst beyond metrics.
Article argues AbbVie’s forward valuation (forward P/E ~15) and free cash flow (~$20B) support its dividend and growth despite high trailing P/E.
Low near-term impact; could support incremental dip-buying sentiment.
Background
The S&P 500 is described as expensive and resilient amid geopolitical/oil and rate-concern headlines; the article pivots to dividend-stock valuation comparisons.
Why it matters
For ABBV/CVS/VZ, the trading takeaway is mainly valuation + dividend safety framing (forward P/E, free cash flow vs dividends, payout ratios) rather than a new fundamental event.
Market relevance
Valuation-and-dividend thesis may influence income-focused positioning, but lacks a discrete catalyst for a high-conviction trade.
Market effects
Supports a defensive rotation narrative into healthcare/telecom dividend payers when broad indices look expensive.
Primarily US equity sentiment; could influence US dividend ETF flows.
Limited direct global linkage; mostly US income/valuation positioning.
Alternative perspectives
Dividend coverage and forward P/E can look attractive, but the article may underweight duration risk (rates) and sector-specific regulatory/competitive pressures not discussed here.
No discussion of near-term catalysts (earnings date, guidance changes, litigation/regulatory updates), and the “bargain” framing depends heavily on forward estimates.
Key entities
- companyAbbVie
Dividend-paying pharma company; article cites forward P/E (~15) and free cash flow (~$20B) supporting dividend coverage.
- companyCVS Health
Healthcare/insurance/pharmacy operator; article cites improving resilience, free cash flow (~$7.4B) vs dividends (~$3.4B), forward P/E (~12).
- companyVerizon Communications
Telecom dividend payer; article cites ~5.9% yield, forward P/E (~10), payout ratio <70%, and adjusted earnings growth (5%-6%).
